Abstract Purpose of Review The goal of this review is to summarize the current knowledge of
the epidemiology, clinical manifestations, diagnosis, and treatment of cutaneous, mucosal …

Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is
caused by over 15 different species of the protozoan parasite genus Leishmania. There are …

In India, 320 patients with visceral leishmaniasis (209 in the state of Bihar and 11 in the
neighboring state of Uttar Pradesh) received identical pentavalent antimony (Sb) treatment …

Throughout the world, pentavalent antimonial compounds (Sbv) have been the mainstay of
antileishmanial therapy for more than 50 years. Sbv has been highly effective in the …

Leishmaniasis is a parasitic disease that presents four main clinical syndromes: cutaneous
leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), visceral leishmaniasis/kala azar …

Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …

In the recent past the standard treatment of kala‐azar involved the use of pentavalent
antimonials Sb (V). Because of progressive rise in treatment failure to Sb (V) was limited its …

Background Some 50% of patients with visceral leishmaniasis (kala-azar) worldwide live in
the Indian state of Bihar. Liposomal amphotericin B is an effective treatment when …

Background. Miltefosine is the only oral drug available for treatment of Indian visceral
leishmaniasis (VL), which was shown to have an efficacy of 94% in a phase III trial in the …

Background Improved treatment approaches are needed for visceral leishmaniasis. We
assessed the efficacy and safety of three potential short-course combination treatments …